Inmed submits form 12b-25

Vancouver, british columbia, feb. 09, 2023 (globe newswire) -- inmed pharmaceuticals inc. (“inmed” or the “company”) (nasdaq: inm), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announces it has submitted a form 12b-25 with the u.s. securities and exchange commission (the “sec”) in connection with its quarterly report on form 10-q for the period ended december 31, 2022 (the “form 10-q”).
INM Ratings Summary
INM Quant Ranking